Clinical trials: Nausea and Vomiting, Chemotherapy-Induced
Malignant Solid Tumors, Moderate to High Emetogenic Chemotherapy (MEC/HEC) Drugs
Nanocrystalline Megestrol for Managing Chemotherapy-Induced Nausea and Vomiting
The goal of this clinical trial is to learn if medroxyprogesterone acetate oral suspension (Meishiya®) works to prevent nausea and vomiting caused by single-day moderate to high emetogenic chemotherapy (MEC/HEC) in the…
- Trial name
- NCT07124195
- Testing
- Medroxyprogesterone acetate oral suspension, high antiemetic regimen, moderate antiemetic regimen
- Where
- China
- Volunteers
- 126 people
- Sponsor
- The First Affiliated Hospital of Xinxiang Medical College
Chemotherapy Induced Nausea and Vomiting
Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 Years
The purpose of this study is to determine the dosing strategy for adolescents aged 6 to 12 years.
- Trial name
- NCT01596413
- Testing
- Sancuso, IV granisetron
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Chemotherapy-induced Nausea and Vomiting
Steroid-sparing Therapy (Olanzapine) Versus Dexamethasone-based Therapy for Chemotherapy-induced Nausea and Vomiting
The purpose of this research is to compare two drugs that are routinely used as standard of care for treating nausea and vomiting caused by chemotherapy.
- Trial name
- NCT05590923
- Testing
- OLA group: Olanzapine, DEX group: Dexamethasone
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- The Guthrie Clinic
Chemotherapy-induced Nausea and Vomiting
Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting
The purpose of the study is to mainly evaluate the efficacy and safety of aprepitant in combination with olanzapine ,palonosetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients…
- Trial name
- AOPDPCINV (NCT02484911)
- Testing
- Olanzapine, Aprepitant, Palonosetron
- Where
- China
- Volunteers
- 120 people
- Sponsor
- First Affiliated Hospital of Harbin Medical University
Chemotherapy-induced Acute or Delayed Nausea and Vomiting (CINV)
Phase 4 Trial to Evaluate the Efficacy and Safety of Sancuso Patch in Chemotherapy-induced Nausea and Vomiting Associated With the Administration of Highly Emetogenic Chemotherapy (HEC)
This is a multicenter, randomized, open-label, paralleled-group, active-controlled study. The study is to demonstrate non-inferiority of the Granisetron Transdermal Delivery System (GTDS) efficacy compared with the ondansetron…
- Trial name
- NCT01659775
- Testing
- Sancuso patch, Zofran inj.+Zofran tab.
- Where
- South Korea
- Volunteers
- 389 people
- Sponsor
- LG Life Sciences
Breast Cancer, Drug-induced Nausea and Vomiting
Acupressure in Treating Nausea in Women Receiving Combination Chemotherapy for Breast Cancer
RATIONALE: Acupressure may help to reduce or prevent nausea in patients who are undergoing chemotherapy. It is not yet known whether acupressure plus standard care for nausea is more effective than standard care alone for nausea…
- Trial name
- NCT00046865
- Testing
- acupressure therapy, management of therapy complications, nausea and vomiting therapy
- Where
- 2 sites in United States
- Volunteers
- 57 people
- Sponsor
- M.D. Anderson Cancer Center
Chemotherapy-Related Nausea and/or Vomiting, Early Stage Breast Carcinoma
Evaluating the Association Among Changes in Gut Microbiome, Fatigue, and Chemotherapy-Induced Nausea in Early Stage Breast Cancer
This pilot study seeks to understand how changes in the bacteria composition (microbiome) of the gut may be associated with the occurrence of fatigue and chemotherapy-induced nausea (CIN) in women undergoing chemotherapy for…
- Conditions
- Chemotherapy-Related Nausea and/or Vomiting, Early Stage Breast Carcinoma, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT05417867
- Testing
- Biospecimen Collection, Questionnaire Administration
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- Mayo Clinic
Chemotherapy-induced Nausea and Vomiting
Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma
The purpose of this study is to investigate the effectiveness of intravenous fosaprepitant therapy to reduce nausea and vomiting during the treatment of high dose interleukin-2 (HD IL-2) therapy for metastatic melanoma or…
- Trial name
- HDIL2/Emend (NCT01874119)
- Testing
- Fosaprepitant
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- St. Louis University
Breast Carcinoma
Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer
This randomized phase III trial studies how well netupitant/palonosetron hydrochloride and dexamethasone with prochlorperazine or olanzapine work compared to netupitant/palonosetron hydrochloride and dexamethasone in improving…
- Trial name
- NCT03367572
- Testing
- Dexamethasone, Laboratory Biomarker Analysis, Netupitant/Palonosetron Hydrochloride
- Where
- 18 sites in United States
- Volunteers
- 1,363 people
- Sponsor
- University of Rochester NCORP Research Base
Vomiting
Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)
This study is being conducted to demonstrate that aprepitant (MK-0869) prevents nausea and vomiting caused by emetogenic cancer chemotherapy in adolescent participants.
- Trial name
- NCT00080444
- Testing
- aprepitant, ondansetron, dexamethasone
- Volunteers
- 50 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-induced Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer
The goal of this clinical research study is to learn if adding dronabinol in combination with the standard of care (dexamethasone and palonosetron) can better help to control nausea and vomiting in patients receiving…
- Trial name
- NCT00553059
- Testing
- dexamethasone, dronabinol, palonosetron hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 62 people
- Sponsor
- M.D. Anderson Cancer Center
Nausea With Vomiting Chemotherapy-Induced
Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 Blockade
The aim of this randomized study is to compare the efficacy and safety of ondanstron weekly with every 3 weeks for the prevention of nausea and vomiting induced by chemotherapy combined with PD-1 blockade.
- Trial name
- NCT06080880
- Testing
- Ondansetron every 3 weeks, Aprepitant, Dexamethasone
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Hubei Cancer Hospital
Breast Cancer, Malignant Female Reproductive System Neoplasm
Effect of Yoga in Reducing Chemotherapy Induced Nausea and Vomiting
This randomized controlled three arm study compares the effects of a yoga intervention with jacobsons progressive muscle relaxation training and only standard of care in chemotherapy naive cancer patients.
- Conditions
- Breast Cancer, Malignant Female Reproductive System Neoplasm, Lymphomas, Chemotherapy-induced Nausea and Vomiting
- Trial name
- NCT01387841
- Testing
- yoga, Jacobsons PMRT group
- Where
- India
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Bharath Charitable Cancer Hospital and Institute
Breast Cancer Female, Acupuncture
Electric Stimulation on Nausea and Vomit Chemotherapy Induced
Chemotherapy induces nausea and vomit for some large patients. But, some chemotherapy protocol has a high indices of the incidence as observed in a combination of Anthracycline and Cyclophosphamide (AC).
- Trial name
- TENS-NV (NCT03145727)
- Testing
- Low Frequency Group, High Frequency Group
- Where
- 2 sites in Brazil
- Volunteers
- 84 people
- Sponsor
- Federal University of Health Science of Porto Alegre
Chemotherapy-Induced Nausea and Vomiting
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)
This study will determine the appropriate dosing regimen of aprepitant and fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric participants from 0 months to 17 years of age.
- Trial name
- NCT00818259
- Testing
- Experimental: aprepitant, Experimental: fosaprepitant, Comparator: ondansetron
- Volunteers
- 92 people
- Sponsor
- Merck Sharp & Dohme LLC
Neoplasms, Chemotherapy-induced Nausea and Vomiting
Serious Gaming for Chemotherapy-induced Nausea and Vomiting
The purpose of this study is to examine the effectiveness of a technology-based intervention for managing nausea and vomiting in older adults with cancer.
- Trial name
- NCT05838638
- Testing
- eSSET-CINV
- Where
- 2 sites in United States
- Volunteers
- 610 people
- Sponsor
- University of Central Florida
Chemotherapy-Induced Nausea and Vomiting
An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
NETU-08-18 is a two-arm clinical study assessing efficacy and safety of a single oral dose of netupitant and palonosetron, two antiemetic drugs, versus oral palonosetron, both given with oral dexamethasone.
- Trial name
- NCT01339260
- Testing
- Netupitant and Palonosetron, Palonosetron, Dexamethasone
- Where
- 172 sites in United States, Argentina and 13 more
- Volunteers
- 1,455 people
- Sponsor
- Helsinn Healthcare SA
Breast Neoplasms
Phase 3 Study of Acupression's Bracelets in Nausea and Vomiting Induced by FEC100 Chemotherapy's Sort.
The purpose of this study is to demonstrate a betterment of the digestive symptomatology by the anti-emetic acupression's bracelets's use associated with hygiene and dietetic advices.
- Trial name
- NCT00268125
- Testing
- Acupression's bracelet, Hygiene and dietetic advices
- Where
- 3 sites in France
- Volunteers
- 347 people
- Sponsor
- Institut Claudius Regaud
Chemotherapy-Induced Nausea and Vomiting (CINV)
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)
This study aims to demonstrate that, when given concomitantly with a 5-hydroxytryptamine 3 (5-HT3) antagonist and a corticosteroid, a single 150 mg intravenous (IV) dose of fosaprepitant given on Day 1 is superior to the control…
- Trial name
- NCT01594749
- Testing
- Fosaprepitant dimeglumine, Dexamethasone, Ondansetron
- Volunteers
- 1,015 people
- Sponsor
- Merck Sharp & Dohme LLC
Nausea and Vomiting
A Phase IV Trial of Cesamet™ Given With Standard Antiemetic Therapy for Chemotherapy-induced Nausea and Vomiting
This is a Phase IV, open-label, sequential treatment study in patients who are receiving standard chemotherapy for non-small cell lung cancer, breast cancer, or colorectal cancer.
- Trial name
- NCT00418678
- Testing
- Cesamet
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Veeda Oncology